O Orexo AB
O
Avatud
18.08 0.11
Ülevaade
Aktsiahinna muutus
24h
Min
18.08
Max
18.54
Sissetulek | -68M -116M |
|---|---|
Müük | -115M 3.3M |
Aktsiakasum | 20.884 |
Kasumimarginaal | -3,503.03 |
Töötajad | 74 |
EBITDA | -262M -272M |
Järgmine tulemuste avaldamine | 16. juuli 2026 |
|---|
Turukapital | -334M 700M |
|---|---|
Eelmine avamishind | 17.97 |
Eelmine sulgemishind | 18.08 |
Orexo AB Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Orexo AB Prognoos
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Orexo AB
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
